Drug delivery method
US10117912B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 31, 2014 |
| Grant date | Nov 6, 2018 |
| Priority date | — |
| Expiry date | Aug 9, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21063
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a new drug delivery strategy based on prodrug conversion, in which a water-soluble prodrug and its converting enzyme are co-delivered and at a point of administration such as the nasal or buccal mucosa. Enzymatic conversion of the prodrug produces drug in concentrations exceeding the drug's thermodynamic solubility, or saturation level. The supersaturated drug crosses the mucosal membrane quickly, as a result of its high thermodynamic activity, prior to crystallization. This strategy is particularly useful when fast action is required, for example in preventing or responding rapidly to Status Epilepticus (SE) or other central nervous system conditions such as migraine.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.